UNITED STATES SECURITIES AND EXCHANGE COMMISSION Form 144 Filer Information Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001055951 Filer CCC XXXXXXXX Is this a LIVE or TEST Filing? LIVE O TEST Submission Contact Information

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value		Approximate Date of Sale	Name the Securities Exchange
Common Stock	Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York NY 10036	585274	421397.00	27112697	10/02/2023	Nasdaq Stock Market

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you Nature of

Name of

Is Date Amount of

Nature of

Date of

Galecto, Inc.
001-39655
75 State Street
Suite 100
Boston
MASSACHUSETTS
02109
45-70-70-52-10
OrbiMod Drivato Invocto

OrbiMed Private Investments VII, LP

Class	Acquired	Acquisition Transaction	Person from Whom Acquired		Securities Acquired	Payment	Payment *
Common Stock	10/23/2018 Pr	rivate placement	Issuer		585274	10/23/2018 Ca	sh

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Securities Sale Sold	Gross Proceeds
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/13/2023 132100	317040.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/25/2023 26700	77964.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	07/31/2023 153078	459234.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/15/2023 595534	446651.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/21/2023 49103	30615.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/22/2023 30401	18841.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/23/2023 63287	39981.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/24/2023 48053	29652.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/25/2023 27678	16628.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/28/2023 22043	12289.00
OrbiMed Private Investments VII, LP 601 Lexington Ave.	Common Stock	08/29/2023 41983	24102.00

54th Floor New York NY 10022			
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/30/2023 37865	21962.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	08/31/2023 31667	19317.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/01/2023 78126	47567.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/05/2023 37931	22759.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/06/2023 51019	29081.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/07/2023 13297	7579.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/08/2023 29491	16810.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/11/2023 42108	23580.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/12/2023 202096	125300.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/13/2023 54743	34595.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/14/2023 21539	13295.00
OrbiMed Private Investments VII, LP 601 Lexington Ave. 54th Floor New York NY 10022	Common Stock	09/15/2023 42671	25792.00

144: Remarks and Signature

Remarks OrbiMed Capital GP VII LLC is the general partner of OrbiMed Private Investments VII, LP. OrbiMed Advisors LLC is the managing member of OrbiMed Capital GP VII LLC.

Date of Notice 10/02/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading

instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Douglas Coon, Chief Compliance Officer, OrbiMed Advisors LLC, managing member of the general partner of OrbiMed Private Investments VII, LP

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)